루트K

195990KOSDAQ특수 목적용 기계 제조업

39.5 / 100

Reference Date: 2026-07-24

Financial Score14.0 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 13.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

AB ProBio operates three core business segments: a machine tool division specializing in small machining centers (UT and MAX series), a biopharmaceutical development division that acquired rights to develop dual-antibody drugs targeting HER2 and VEGF from Abpro Corporation, and a semiconductor equipment division expanded through the acquisition of ANAH in 2023. The company produces high-performance machining centers tailored for IT and electronics manufacturing, while advancing biopharmaceutical R&D in Asia, CIS countries, and the Middle East.

Number of Employees

43people

Average Salary

0.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 18.674.0Point

PBR

0.38Industry Average 1.027.0Point

Half of industry avg (excellent)

ROE

-60.38Industry Average 1.160.0Point

Well below industry avg

Debt Ratio

22.87Industry Average 7.710.0Point

3.0x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲12.8% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -31.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 630Won52-week high 3,38252-week low 630

1-month return1.0Point

1m -13.34% (falling)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-07-07